News Release

European marketing authorization application for *Ikervis* has been filed to the EMA for the treatment of Dry Eye Disease

December 6, 2013, Osaka, Japan– Santen Pharmaceutical, Co., Ltd. (Santen), a global pharmaceutical company specialized in the fields of ophthalmology, today announces that an European Marketing Authorization Application (MAA) for *Ikervis* (generic name: Ciclosporin, development code: Cyclokat) has been filed to the European Medicines Agency (EMA) for the treatment of Dry Eye Disease on December 6, 2013. In doing so, the EMA will begin its regulatory review process of the MAA. The application includes safety and efficacy data from *Ikervis*'s clinical program which was conducted in Europe.

The filing of the application for *Ikervis* to the European Medicines Agency is an important step forward in the development of the Santen's Dry Eye franchise.

Santen Pharmaceutical contact

Takashi Hibi
General Manager
Corporate Communication Group
Santen Pharmaceutical, Co., Ltd.
4-20 Ofukacho,
Kita-ku, Osaka 530-8552 Japan
Tel: +81-6-4802-9360

Forward-looking Statements

Information provided in this press release contains so-called "forward looking statements". The realization of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by governments in Japan and other nations concerning medical system, drug pricing and other systems, as well as fluctuations in market variables such as interest and foreign exchange rates.